VIDEO: Research updates in myelodysplastic syndrome from SOHO 2024
Click Here to Manage Email Alerts
In this interview, Naval Daver, MD, discusses a session on myelodysplastic syndrome from Society of Hematologic Oncology Annual Meeting.
Guillermo Garcia-Manero, MD, professor in the department of leukemia at The University of Texas MD Anderson Cancer Center and president of the Society of Hematologic Oncology, and Rami Komrokji, MD, vice chair of the malignant hematology department at the Moffitt Cancer Center, led the session.
“It looks like, in the low-risk [myelodysplastic syndrome (MDS)] setting, we are making a lot of progress, especially in terms of achieving cytopenia improvement transfusion independence, which leads to better quality of life, less admissions, less time in the infusion unit.” Daver, professor and director of the Leukemia Research Alliance Program in the department of leukemia at The University of Texas MD Anderson Cancer Center, told Healio. “However, in the high-risk, or MDS with excess blast, there’s still a lot of unmet need.”
Reference:
- Garcia-Manero G, et al. Session II: Myelodysplastic syndromes. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 4-7, 2024; Houston.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts